Summary
-
Early intervention is clearly an important strategy for the prevention of postmenopausal osteoporosis.
-
Prevention of osteoporosis with HRT can still be considered a first-line strategy, but risks and benefits need to be assessed in each individual case. Such treatment leads to improved longevity and quality of life. It also relieves menopausal symptoms and decreases the incidence of other menopause-related conditions affecting the urogenital and central nervous systems. It may, however, have some undesirable adverse effects.
-
An alternative for estrogens to prevent osteoporosis is raloxifine. Other anti-resorptive drugs, such as bisphosphonates, play an important role in preventing osteoporosis and bone fractures. Calcitonin has only a limited place in therapy.
-
The roles of calcium intake and physical activity are secondary in the prevention of osteoporosis during the early postmenopause. rhPTH may be a promising agent for the future, but it is more likely to be used for the treatment than the prevention of osteoporosis.
The development of osteoporosis depends on both the peak bone mass attained and its subsequent loss. Peak bone mass is achieved in early adulthood and is determined largely genetically. To a lesser extent, bone mass is dependent on diet, exercise, alcohol consumption, smoking, drugs (e.g, corticosteroids, contraceptive pills), parity, and the presence or absence of ovarian function.
The development of osteoporosis results from an imbalance between bone resorption and bone formation. The loss of gonadal function and aging are the two most important factors. Starting around the fourth or fifth decade of life, men and women lose 0.3–0.5% of bone a year. After the loss of gonadal function, this is increased by up to tenfold in women due to an increase in bone turnover.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Further Reading
Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362: 419–27.
Cummings SR, Black DM, Thompson DE, et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 280: 2077–2082.
Dawson-Hughes B (1995) Prevention. In: Riggs BL, Melton LJ III (eds). Osteoporosis 2nd edn. Philadelphia: Lippincott-Raven, pp. 335–350.
Ellerington MC, Hillard RC, Whitcroft SIJ, et al. (1996) Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 59: 6–11.
Gallagher JC, Baylink DJ, Freeman R, McClung M (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomised, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86: 4717–4726.
Hanley DA, Loannidis G, Adachi JD (2000) Etidronate therapy in the treatment and prevention of osteoporosis. J Clin Densitom 3: 79–95.
Lees B, Stevenson JC (2001) The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17/3 and dydrogesterone. Osteoporos Int 12: 251–258.
McClung MR, Geusens P, Miller PD, et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333–340.
Neer RM, Arnaud CD, Zanchetta JR, et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.
Spencer CP, Stevenson JC (1997) Oestrogens and anti-oestrogens for the prevention and treatment of osteoporosis. In: Meunier P (ed.). Osteoporosis: Diagnosis and Management. London: Martin Dunitz, pp. 111–122.
Stevenson JC (1996) Benefitsand risks of hormone therapy. In: Weatherall DJ, Ledingham JGG, Warren DA (eds). Oxford Textbook of Medicine, 3rd edn. Oxford: Oxford Medical Publication, 1813–1815.
Stevenson JC (1998) Is there a case for target ing hormone replacement therapy for osteoporos is at the menopause? Osteoporos Int 8 (supplement I): 47–50.
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.
Rights and permissions
Copyright information
© 2004 Springer-Verlag London
About this chapter
Cite this chapter
Stevenson, J.C. (2004). Prevention Early After Menopause. In: Osteoporosis in Clinical Practice. Springer, London. https://doi.org/10.1007/978-0-85729-402-9_14
Download citation
DOI: https://doi.org/10.1007/978-0-85729-402-9_14
Publisher Name: Springer, London
Print ISBN: 978-1-85233-757-5
Online ISBN: 978-0-85729-402-9
eBook Packages: Springer Book Archive